OSSIO Boosts Commercial Growth with $27.6 Million Funding

OSSIO, Inc., a rapidly expanding medical device company, has secured $27.6 million in equity funding to accelerate its commercial initiatives, focusing on bio-integrative fixation technology. The company aims to scale its operations, including developing new product pipelines, enhancing its sales channels, medical education, and establishing a U.S. manufacturing site in Florida. OSSIO's implants, known for providing strong fixation without leaving permanent metal residues, are positioned as a differentiated solution in the $16 billion orthopedic fixation market. The funding round was led by Questa Capital, with participation from existing investors. The investment will bolster OSSIO's efforts to expand its market presence in the U.S. and select international markets, strengthening its sales team and securing long-term manufacturing capacity. The company has already seen significant success since its first product launch, with over 50,000 OSSIOfiber implants utilized in various procedures. Questa Capital, known for investing in healthcare companies with disruptive technology, sees OSSIO as a clear fit for its strategy of supporting innovative solutions in healthcare. The funding will enhance OSSIO's capacity to grow and innovate in orthopedic surgery.